Perrigo's birth control pill set for FDA adcomm

Today's Big News

Mar 28, 2023

Novartis to ride with Bicycle in radiopharmaceuticals deal that could cruise to $1.7B


J&J adds medtech head Ashley McEvoy to list of highest-paid execs with $7.4M payout in 2022


FDA committee will hear Perrigo's OTC bid for birth control med Opill in May


Ferring shuts down U.S.-based research institute after more than 25 years, cutting nearly 90 employees


After Twist and Ginkgo campaigns, Scorpion Capital aims stinger at Harmony Biosciences

 

Featured

Novartis to ride with Bicycle in radiopharmaceuticals deal that could cruise to $1.7B

Novartis has hopped on Bicycle Therapeutics’ radio-conjugates ride with a $50 million upfront payment and a further $1.7 billion possible down the road.
 

Top Stories

J&J adds medtech head Ashley McEvoy to list of highest-paid execs with $7.4M payout in 2022

For the first time in at least a decade, the head of Johnson & Johnson’s medtech division is among the company’s highest-paid executives.

FDA committee will hear Perrigo's OTC bid for birth control med Opill in May

The FDA has identified a date for its long-awaited advisory committee meeting to discuss whether Perrigo’s birth control medication Opill can be used without a prescription. The joint meeting of the Nonprescription Drugs Advisory Committee (NDAC) and the Obstetrics, Reproductive and Urologic Drugs Advisory Committee (ORUDAC) has been set for May 9-10.

Ferring shuts down U.S.-based research institute after more than 25 years, cutting nearly 90 employees

Ferring Pharmaceuticals is closing up a U.S. research wing, laying off 89 employees as a result. The Ferring Research Institute has been in business since 1996 and just wrapped up a new expansion project.

After Twist and Ginkgo campaigns, Scorpion Capital aims stinger at Harmony Biosciences

Short seller Scorpion Capital was all venom in a new report rebuking Harmony Biosciences and its narcolepsy drug Wakix. The firm branded Harmony’s rollout one of the most “thoroughly corrupt healthcare schemes in recent years.”

Masimo's new privacy-minded smartwatch enters consumer wearable war

Masimo’s first smartwatch gathers data every second. Its second caters to those who may be wary of where, exactly, those 86,400 daily measurements go.

Boehringer puts $481M on the line to pursue emerging cancer target in Covant team-up

Boehringer Ingelheim has spied an opportunity to seize the holy grail of immuno-oncology: turning cold tumors hot. In return for $10 million upfront and up to $471 million milestones, the German drugmaker has tasked Covant Therapeutics with discovering covalent candidates against an emerging cancer target.

Amicus nabs EU nod for Pompe disease newcomer Pombiliti, setting up fight with Sanofi

Amicus Therapeutics' Pombiliti—which combines a long-term enzyme replacement therapy with the oral enzyme stabilizer miglustat—has been approved by the European Commission as Pombiliti in adults with late-onset Pompe disease. Now, the company must wait on the European Medicines Agency’s Committee for Medicine Products for Human Use to deliver a verdict on miglustat specifically.

SunMed charts new dawn with respiratory consumables catalog from Vyaire Medical

The deal includes single-use oxygen delivery systems and devices for opening the patient’s airway, such as positive-pressure ventilation masks and tubing. The financial terms of the transaction were not disclosed.

With another wave of layoffs and CEO exit, AMT seeks out 'strategic alternatives'

With its lead chronic pouchitis treatment stuck in limbo as the company searches for a phase 3 partner, it looks like Applied Molecular Transport has finally thrown in the towel.

Esperion, Daiichi Sankyo milestone payment feud heats up with new lawsuit

Milestone payments can be hard to come by when two partners can't agree on trial results. Now, Esperion slapped its Nexletol partner Daiichi Sankyo with a lawsuit after the latter refused a $300 million payout.
 
Fierce podcasts

Don't miss an episode

'The Top Line': Fierce Medtech's annual Fierce 15 honorees

This week on "The Top Line," we discuss Fierce Medtech’s annual Fierce 15 report and startups that made the cut. We also cover Illumina and Carl Icahn's proxy battle and more of this week's top headlines.

 

Resources

Whitepaper

Plan for scalable process liquid and buffer preparation

Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation.
Whitepaper

US/EU Governance: The Importance of Company Culture and Proven, Real-World Solutions

This paper describes the key elements of good US/EU corporate governance for US-based biopharma companies in operating Europe.
Executive Summary

Optimizing drug discovery in a fast-moving market

Read about the latest survey results from over 200 biopharma executives and the changing approaches to building biologic drug development pipelines.
Whitepaper

Answering your specific questions about mRNA/saRNA manufacturing

Have you had your questions about mRNA/saRNA manufacturing unanswered during a webinar; have no fear, we have you covered here.
Whitepaper

Proven Pharmaceutical Go-To-Market Model

Download Herspiegel Consulting’s Go-To-Market Model, based on 100+ launches, to learn the critical components, and timelines for commercial success.

Whitepaper

Intranasal Drug Product Development: Formulation to Manufacturing

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?
Whitepaper

Running Decentralized Trials at Scale

Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment.
Research

Step-wise strategy to address process characterization and late phase development

Learn more on Catalent’s step-wise approach for the definition and execution of Process Characterization for the production of a monoclonal antibody for late phase process characterization and development.

Whitepaper

Designing an Optimal APAC Clinical Supply Chain

Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific.
Whitepaper

Key Clinical Supply Issues Sponsors Should Consider with their CRO

As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs.

Research

A Strategy to Standardize Process Characterization & Late Phase Development

Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments.

Whitepaper

Specialized Expertise for Management of Clinical Supply Budgets

For sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management.
Whitepaper

Clinical Supply Solutions for the Asia-Pacific Region

Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region.
Whitepaper

Roles and Responsibilities of Specialized Clinical Supply Experts

How can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis.
Whitepaper

Questions You Need to Ask Your CRO About Clinical Supply

Planning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial.
Whitepaper

Supply Services to Support Clinical Trials in Japan & Beyond

Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world.
 

Industry Events

 

Upcoming Fierce Events

3-4
Apr
San Diego, CA
1-3
May
May 1-3, 2023 | Jersey City, NJ
12-14
Jun
San Diego, CA
13-14
Jun
Free Virtual Event
20-22
Jun
Free Virtual Event

View all events